Crestline Management, LP Savara Inc Transaction History

Crestline Management, LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2018 Nov 14, 2018	SELL	$10.49 - $12.87 $787,788 - $966,524	-75,099 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$8.55 - $13.76 $642,096 - $1.03 Million	75,099 New	75,099 $850,000

138

152M

60.6K

12.3K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $322M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

Stay updated on Crestline Management, LP with notifications on news.